Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

I-Mab Reports Third Quarter 2024 Results

* Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data * On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 * Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 * Estimated cash ru...

2024-11-14 20:00 1075

Transforming Healthcare with Real-Time AI Image Analytic

Join us to discover how NVIDIA IGX and SDVoE enable seamless ultra-low latency solutions TAIPEI, Nov. 14, 2024 /PRNewswire/ -- Advantech announces enhanced AI detection for endoscopy surgical systems with the integration of its MIC-735M-IO, powered by NVIDIA IGX™, and the VEGA series ultra-low-l...

2024-11-14 18:37 1252

Transforming Healthcare with Real-Time AI Image Analytic

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...

2024-11-13 23:51 1053

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

Datasea Reports First Quarter 2025 Revenue of $21 Million, Up 206% Year-over-Year

Datasea's Top-Line Performance Driven by its Further Penetration of China's 5G AI Applications Segment BEIJING, Nov. 13, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology firm, today released its financial results for its first fiscal quarter...

2024-11-13 22:30 1957

Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network

Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, Nov. 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic alliance with VIDI Group, the lar...

2024-11-13 22:00 1601

Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network

Concord Medical Schedules 2024 Annual Meeting of Shareholders

BEIJING, Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it will hold its 2024 annual general meeting o...

2024-11-13 21:00 1543

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...

2024-11-12 21:15 1432

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, ...

2024-11-12 18:09 1012

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke proudly concluded its participation in BIO-Europe 2024, held fromNovember 4 to 6 inStockholm, Sweden. As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees ...

2024-11-12 17:07 982

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Glo...

2024-11-12 08:00 1208

HoneyNaps AI Diagnostic Medical Software as Featured in International Journal "Digital Health"

- Published clinical study on sleep apnea patients in the prestigious journal Digital Health - Clinical research on HoneyNaps SOMNUM validates its clinical efficacy BOSTON, Nov. 11, 2024 /PRNewswire/ -- Medical AI company HoneyNaps has published a paper demonstrating the clinical value and effic...

2024-11-11 22:00 940

HoneyNaps AI Diagnostic Medical Software as Featured in International Journal

Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...

2024-11-11 21:45 1643

DermRays Revolutionizing At-Home Laser Hair Removal with Innovative New Products

PLEASANTON, Calif., Nov. 11, 2024 /PRNewswire/ -- As anticipation grows around DermRays' latest developments, industry insiders are abuzz with speculation about the future direction of the company's product line. Whether through a potential upgrade to theV8S Pro

2024-11-11 21:00 824

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...

2024-11-11 20:30 1137

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...

2024-11-11 08:07 1318

Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO)& 4th International Congress of the Asian Oncology Society (AOS2024)

XI'AN, China, Nov. 9, 2024 /PRNewswire/ -- On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International Congress of the Asian Oncology Society (AOS2024) . This esteemed ...

2024-11-09 14:45 3551

Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based Antibody-drug Conjugate for the Treatment of Solid Tumors" as a poster presentation at the 15 t...

2024-11-08 22:00 2405

Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...

2024-11-08 22:00 2671

Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024

Samsung Biologics earns ISO certifications in recognition of business excellence

* The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security * Certifications recognize Samsung Biologics' commitment to operational excellence and demonstrates the company's reliability and integrity as a trusted CDM...

2024-11-08 20:00 1498

Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20ins SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Dizal (SSE:68...

2024-11-08 18:01 1270

1 ... 6 7 8910 11 12 ... 219